Proteomic insight towards key modulating proteins regulated by the aryl hydrocarbon receptor involved in ovarian carcinogenesis and chemoresistance

被引:2
作者
Therachiyil, Lubna [1 ,2 ]
Peerapen, Paleerath [3 ]
Younis, Shahd M. [2 ]
Ahmad, Aamir [2 ,4 ]
Thongboonkerd, Visith [3 ]
Uddin, Shahab [2 ,4 ]
Korashy, Hesham M. [1 ,5 ]
机构
[1] Qatar Univ, Coll Pharm, Dept Pharmaceut Sci, QU Hlth, Doha, Qatar
[2] Hamad Med Corp, Translat Res Inst, Doha, Qatar
[3] Mahidol Univ, Fac Med Siriraj Hosp, Res Dept, Med Prote Unit, Bangkok, Thailand
[4] Hamad Med Corp, Dermatol Inst, Dept Dermatol & Venereol, Doha, Qatar
[5] Qatar Univ, Coll Pharm, Dept Pharmaceut Sci, POB 2713, Doha, Qatar
关键词
Ovarian Cancer; Aryl hydrocarbon receptor (AhR); 8-tetrachlorodibenzo-p-dioxin (TCDD); Apoptosis; Chemoresistance; Proteomics; HEPATOCELLULAR-CARCINOMA; COMPUTATIONAL PLATFORM; TUMOR-SUPPRESSOR; CANCER; RESISTANCE; DATABASE; DISEASE; CELLS; PEX5;
D O I
10.1016/j.jprot.2024.105108
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Gynecological malignancies pose a severe threat to female lives. Ovarian cancer (OC), the most lethal gynecological malignancy, is clinically presented with chemoresistance and a higher relapse rate. Several studies have highly correlated the incidence of OC to exposure to environmental pollutants, such as 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), a process mainly mediated through activating the aryl hydrocarbon receptor (AhR). We have previously reported that exposure of OC cells to TCDD, an AhR activator, significantly modulated the expression of several genes that play roles in stemness and chemoresistance. However, the effect of AhR activation on the whole OC cell proteome aiming at identifying novel druggable targets for both prevention and treatment intervention purposes remains unrevealed. For this purpose, we conducted a comparative proteomic analysis of OC cells A2780 untreated/treated with TCDD for 24 h using a mass spectrometry-based label-free shotgun proteomics approach. The most significantly dysregulated proteins were validated by Western blot analysis. Our results showed that upon AhR activation by TCDD, out of 2598 proteins identified, 795 proteins were upregulated, and 611 were downregulated. STRING interaction analysis and KEGG-Reactome pathway analysis approaches identified several significantly dysregulated proteins that were categorized to be involved in chemoresistance, cancer progression, invasion and metastasis, apoptosis, survival, and prognosis in OC. Importantly, selected dysregulated genes identified by the proteomic study were validated at the protein expression levels by Western blot analysis. In conclusion, this study provides a better understanding of the the cross-talk between AhR and several other molecular signaling pathways and the role and involvement of AhR in ovarian carcinogenesis and chemoresistance. Moreover, the study suggests that AhR is a potential therapeutic target for OC prevention and maintenance. Significance: To our knowledge, this is the first study that investigates the role and involvement of AhR and its regulated genes in OC by performing a comparative proteomic analysis to identify the critical proteins with a modulated expression upon AhR activation. We found AhR activation to play a tumor-promoting and chemoresistance-inducing role in the pathogenesis of OC. The results of our study help to devise novel therapeutics for better management and prevention and open the doors to finding novel biomarkers for the early detection and prognosis of OC.
引用
收藏
页数:12
相关论文
共 68 条
  • [1] Aryl hydrocarbon receptor/cytochrome P450 1A1 pathway mediates breast cancer stem cells expansion through PTEN inhibition and β-Catenin and Akt activation
    Al-Dhfyan, Abdullah
    Alhoshani, Ali
    Korashy, Hesham M.
    [J]. MOLECULAR CANCER, 2017, 16
  • [2] CYP1B1 gene: Implications in glaucoma and cancer
    Alsubait, Arwa
    Aldossary, Wadha
    Rashid, Mamoon
    Algamdi, Amani
    Alrfaei, Bahauddeen M.
    [J]. JOURNAL OF CANCER, 2020, 11 (16): : 4652 - 4661
  • [3] Tumour suppressor EP300, a modulator of paclitaxel resistance and stemness, is downregulated in metaplastic breast cancer
    Asaduzzaman, Muhammad
    Constantinou, Stephanie
    Min, Haoxiang
    Gallon, John
    Lin, Meng-Lay
    Singh, Poonam
    Raguz, Selina
    Ali, Simak
    Shousha, Sami
    Coombes, R. Charles
    Lam, Eric W. -F.
    Hu, Yunhui
    Yague, Ernesto
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2017, 163 (03) : 461 - 474
  • [4] The Aryl Hydrocarbon Receptor Undergoes Chaperone-Mediated Autophagy in Triple-Negative Breast Cancer Cells
    Chen, Jinyun
    Yang, Yujie
    Russu, Wade A.
    Chan, William K.
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (04) : 1 - 26
  • [5] Accurate Proteome-wide Label-free Quantification by Delayed Normalization and Maximal Peptide Ratio Extraction, Termed MaxLFQ
    Cox, Juergen
    Hein, Marco Y.
    Luber, Christian A.
    Paron, Igor
    Nagaraj, Nagarjuna
    Mann, Matthias
    [J]. MOLECULAR & CELLULAR PROTEOMICS, 2014, 13 (09) : 2513 - 2526
  • [6] Andromeda: A Peptide Search Engine Integrated into the MaxQuant Environment
    Cox, Juergen
    Neuhauser, Nadin
    Michalski, Annette
    Scheltema, Richard A.
    Olsen, Jesper V.
    Mann, Matthias
    [J]. JOURNAL OF PROTEOME RESEARCH, 2011, 10 (04) : 1794 - 1805
  • [7] Post-Translational Modification of GPX4 is a Promising Target for Treating Ferroptosis-Related Diseases
    Cui, Can
    Yang, Fei
    Li, Qian
    [J]. FRONTIERS IN MOLECULAR BIOSCIENCES, 2022, 9
  • [8] Peroxisomes and cancer: The role of a metabolic specialist in a disease of aberrant metabolism
    Dahabieh, Michael S.
    Di Pietro, Erminia
    Jangal, Maika
    Goncalves, Christophe
    Witcher, Michael
    Braverman, Nancy E.
    del Rincon, Sonia V.
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2018, 1870 (01): : 103 - 121
  • [9] Involvement of miR-29b signaling in the sensitivity to chemotherapy in patients with ovarian carcinoma
    Dai, Furong
    Zhang, Yi
    Chen, Yuxiang
    [J]. HUMAN PATHOLOGY, 2014, 45 (06) : 1285 - 1293
  • [10] Targeting G6PD reverses paclitaxel resistance in ovarian cancer by suppressing GSTP1
    Feng, Qi
    Li, Xiuru
    Sun, Wenjing
    Sun, Mingming
    Li, Zhen
    Sheng, Hao
    Xie, Fei
    Zhang, Shuai
    Shan, Changliang
    [J]. BIOCHEMICAL PHARMACOLOGY, 2020, 178